Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jessica Merrill
The diversified pharma has two NMEs and three sNDAs pending at FDA in immunology, as well as six more anticipated sNDA filings. Immunology Therapeutic Head Susan Dillon told investors why there is still plenty of opportunity for growth in key autoimmune diseases.
Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.
President-Pfizer Oncology Liz Barrett said the company remains committed to demonstrating the value of Bavencio in first-line lung cancer despite a recent setback that will push data out to 2019.
Ibrance, Xtandi and Bavencio are positioned as three anchor drugs with big market potential and opportunities for expansion, President-Worldwide R&D Mikael Dolsten said at a recent briefing at Pfizer's headquarters.
Biogen acquired rights to Remedy's Cirara, a Phase III-ready candidate in development for large hemispheric infarction, a severe stroke where brain swelling causes high mortality.
FDA issued a complete response letter for Hikma's ANDA to market a generic version of GSK's Advair, the second application to be rejected by FDA.